Delving into the Latest Updates on Talaporfin Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Aptocine, Leserfin, Litx

+ [14]

Target-

Action-

Mechanism

Photosensitizers

Therapeutic Areas

NeoplasmsNervous System DiseasesDigestive System Disorders+ [1]

Active Indication

Esophageal CarcinomaBrain CancerLung Cancer

Inactive Indication

Originator Organization

Meiji Seika Pharma Co., Ltd.

Active Organization

Meiji Seika Pharma Co., Ltd.

Inactive Organization

Light Sciences Oncology, Inc.Light Sciences, Inc.

License Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (16 Oct 2003),

Lung Cancer

RegulationOrphan Drug (Japan)

Login to view timeline

Structure/Sequence

Molecular FormulaC38H37N5Na4O9

InChIKeyJLWROAPZCOJYGT-OBJGRMLXSA-J

CAS Registry220201-34-3

Author: Higuchi, Hirokazu ; Kishimoto, Yo ; Muto, Manabu ; Yokoyama, Akira ; Ohashi, Shinya ; Katada, Chikatoshi ; Sakanaka, Katsuyuki ; Amanuma, Yusuke ; Shimizu, Takahiro ; Yamahigashi, Natsuko ; Nikaido, Mitsuhiro ; Nomura, Motoo ; Tsunoda, Shigeru ; Inoo, Hiroyuki ; Mitani, Yosuke ; Tamaoki, Masashi ; Obama, Kazutaka ; Hirohashi, Kenshiro ; Horimatsu, Takahiro

Abstract:

Background:

Talaporfin sodium photodynamic therapy (Talaporfin-PDT) shows a high local complete response (L-CR) rate for local failure after chemoradiotherapy in esophageal cancer; however, some patients do not achieve L-CR. We investigated the treatment resistance factors associated with Talaporfin-PDT for local control.

Methods:

This study included 55 consecutive patients with ycT1-2 esophageal cancer who received Talaporfin-PDT. We investigated the L-CR rate, cumulative survival rate according to local effect, and treatment resistance factors associated with Talaporfin-PDT for local control using a multivariate logistic regression model.

Results:

The L-CR rate was 65.5% (95% confidence interval [CI]: 52.3–76.6). During the median follow-up of 17.8 months (range, 1.7–69.3), the 1-year overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) rates were significantly higher in patients who achieved L-CR than in those who did not: 97.0% vs. 75.6% ( P = 0.008), 64.6% vs. 0% ( P < 0.001), and 97.0% vs. 85.7% ( P = 0.005), respectively. In the multivariate logistic regression model, esophageal stenosis before Talaporfin-PDT was an independent predictor of local failure after Talaporfin-PDT (odds ratio: 5.626, 95% CI: 1.051–30.124, P = 0.044). The 1-year OS and DSS rates were significantly lower in patients with stenosis before Talaporfin-PDT than in those without: 75.0% vs. 92.4% ( P = 0.015) and 85.7% vs. 94.6% ( P = 0.015), respectively.

Conclusions:

Esophageal stenosis before Talaporfin-PDT was associated with resistance to local control and poor survival. The indications for the use of Talaporfin-PDT in patients with stenosis should be considered carefully.

01 Apr 2026·JOURNAL OF NEURO-ONCOLOGY

Photodynamic therapy using talaporfin sodium for grade 2/3 meningiomas: a preliminary study of safety, feasibility, and clinical outcomes

Article

Author: Fukami, Shinjiro ; Kohno, Michihiro ; Ichimasu, Norio ; Nakajima, Nobuyuki ; Matsushima, Ken ; Akimoto, Jiro ; Saito, Yuki ; Nagai, Kenta ; Onodera, Sho

Abstract:

Purpose:

Atypical and anaplastic (grade 2/3) meningiomas are associated with high recurrence rates and lack effective systemic therapies other than radiotherapy. Photodynamic therapy (PDT) using talaporfin sodium (TPS) generates selective cytotoxicity extending beyond resection margins and may improve local tumor control. Objective is to evaluate the feasibility, safety, and clinical outcomes of additional intraoperative PDT using TPS for grade 2/3 meningioma patients.

Methods:

Nineteen patients with grade 2/3 meningiomas who underwent resection together with PDT at our institute between 2015 and 2025 were retrospectively analyzed. PDT was performed 22 to 26 h after intravenous TPS administration. Tumor location, pathology, Simpson resection grades, history of radiation therapy (RT), and outcomes were reviewed.

Results:

Of the 19 patients, 18 had recurrent tumors, and 10 had prior RT. Tumor sites included skull base (8 patients), parasagittal sinus (6), convexity (2), falx (1), subcutaneous (1), and intraventricular (1). Histology revealed grade 2 (12 patients) and grade 3 (7), with Simpson I (3), II (6), III (2), and IV (8) resections. Median progression-free survival was 12.5 months, and median overall survival after PDT was 54.5 months. The prognosis was more favorable in RT- naïve patients than in those with a history of prior RT before PDT.

Conclusion:

PDT combined with resection is a safe adjunctive strategy for grade 2/3 meningiomas. Our preliminary data suggest that its efficacy is limited in post-radiation recurrences, but it may delay disease progression when applied before RT. PDT should hence be considered as a therapeutic option for grade 2/3 meningiomas.

01 Apr 2026·Photodiagnosis and Photodynamic Therapy

Phase I/II clinical study of next-generation photodynamic therapy (L-PDT) using talaporfin sodium (Laserphyrin®) for cervical intraepithelial neoplasia: Efficacy, safety, and fertility preservation

Article

Author: Hirose, Sou ; Fujiwara, Arisa ; Iwaya, Keiichi ; Sakamoto, Masaru ; Matsuoka, Kazuko ; Takeda, Shuji ; Hirata, Momo ; Okamoto, Aikou ; Tanaka, Tadao ; Umayahara, Kenji

BACKGROUND:

PDT using Photofrin® (P-PDT) has been applied to over 900 gynecologic tumor cases since 1989, demonstrating excellent efficacy and fertility preservation; however, post-treatment photosensitivity has limited its clinical application for CIN and cervical cancer. This study aimed to establish a safe, effective, and fertility-preserving alternative to cervical conization.

METHODS:

To overcome photosensitivity, we conducted a prospective Phase I/II clinical study to evaluate the safety, efficacy, oncological control, and fertility outcomes of L-PDT using talaporfin sodium (Laserphyrin®) and a diode laser for CIN grades 2-3. Forty-three women with biopsy-confirmed CIN2-3 were enrolled. Phase I determined the optimal light dose (50, 75, or 100 J/cm²), and Phase II assessed efficacy and safety at 100 J/cm². Talaporfin sodium (40 mg/m²) was administered intravenously 4 hours before laser irradiation under colposcopic guidance.

RESULTS:

Complete response (CR) was achieved in 95% (95% CI: 89.1-100%) at 3 months and 98% (95% CI: 93.2-100%) at 6 months after treatment. Original high-risk human papillomavirus clearance was 92.5% at 3 months and 95% at 12 months. Adverse events were mild and transient, including abdominal pain and low-grade fever. No recurrences occurred during a median follow-up of 66.4 months among patients achieving CR. Among women desiring pregnancy, the conception rate was 74% (23/31) and the live birth rate was 79% (27/34), with a low preterm birth rate of 3.7% (1/27).

CONCLUSIONS:

These results suggest that L-PDT is a safe and highly effective non-excisional treatment for CIN that may contribute to fertility preservation; however, potential advantages over conventional conization and laser vaporization need to be confirmed in comparative studies.

100 Deals associated with Talaporfin Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01985	Talaporfin Sodium	L01	DB11812

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Esophageal Carcinoma	Japan	Meiji Seika Pharma Co., Ltd.	20 May 2015
Brain Cancer	Japan	Meiji Seika Pharma Co., Ltd.	20 Sep 2013
Lung Cancer	Japan	Meiji Seika Pharma Co., Ltd.	16 Oct 2003

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Carcinoma in situ of uterine cervix	Phase 3	Japan	Meiji Seika Pharma Co., Ltd.	05 Apr 2023
Cervical Intraepithelial Neoplasia	Phase 3	Japan	Meiji Seika Pharma Co., Ltd.	05 Apr 2023
Colorectal Cancer	Phase 3	Austria	Light Sciences Oncology, Inc.	01 Feb 2007
Colorectal Cancer	Phase 3	Bosnia and Herzegovina	Light Sciences Oncology, Inc.	01 Feb 2007
Colorectal Cancer	Phase 3	Croatia	Light Sciences Oncology, Inc.	01 Feb 2007
Colorectal Cancer	Phase 3	Germany	Light Sciences Oncology, Inc.	01 Feb 2007
Colorectal Cancer	Phase 3	India	Light Sciences Oncology, Inc.	01 Feb 2007
Colorectal Cancer	Phase 3	Italy	Light Sciences Oncology, Inc.	01 Feb 2007
Colorectal Cancer	Phase 3	Latvia	Light Sciences Oncology, Inc.	01 Feb 2007
Colorectal Cancer	Phase 3	Poland	Light Sciences Oncology, Inc.	01 Feb 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


UEGW2025	Not Applicable	Oesophageal squamous cell carcinoma recurrent	29	Talaporfin sodium PDT	oxpealbndy(vvwlqmqagm) = Adverse events included esophageal strictures (1 case, asymptomatic) and esophageal perforations (2 cases), one of which required surgical intervention. pqidnjaocw (apyuqwcjus )	Positive	05 Oct 2025
				Talaporfin sodium PDT (single PDT session)
UEGW2023	Not Applicable	Oesophageal squamous cell carcinoma recurrent	-	PDT with Talaporfin Sodium	tcvwbljnbm(zbpuiceage) = tgnoxgpcmu fnfcuubjff (seegbkfcbg ) View more	-	15 Oct 2023
SNO2017	Phase 2	Glioblastoma	-	PDT group (Talaporfin sodium and semiconductor laser)	jskvgxmlik(ttxycgnimp) = gyjmtcopip bqphfdvnlv (getxgyyseh ) View more	Positive	06 Nov 2017
				Control group (surgical removal of tumor without PDT)	jskvgxmlik(ttxycgnimp) = kkrbxplryq bqphfdvnlv (getxgyyseh ) View more
ACTR-39 (SNO2016)	Phase 2	Glioblastoma	-	PDT with Talaporfin sodium and semiconductor laser	ifteneaegl(hijwkvwrec) = bdzvhuteoo losfalkecg (pplzrnyzed ) View more	Positive	07 Nov 2016
				Talaporfin sodium (Surgical resection)	spxchuptbg(qgwvqyqjsr) = yggncnltnv zestxbtbcr (koeqonaimg ) View more
NCT00440310 (CTgov)	Phase 3	Liver metastases \| Colorectal Cancer \| Local Neoplasm Recurrence	483	Interstitial light emitting diodes+leucovorin+irrinotecan+oxaliplatin+fluorouracil+Talaporfin sodium (Litx + Chemotherapy)	bdqpfhztjm(fbfdadfzee) = brfwdmvfak xbkynqvrma (idgjdrmwya, pptlbfwmxa - vgfvumvehg) View more	-	25 Aug 2015
				leucovorin+irrinotecan+oxaliplatin+fluorouracil (Chemotherapy Alone)	bdqpfhztjm(fbfdadfzee) = jkspieyfpj xbkynqvrma (idgjdrmwya, zbjwggmakz - nysfweozat) View more
JPRN-UMIN000003970 (ASCO_GI2012)	Phase 1	Oesophageal squamous cell carcinoma recurrent \| Esophageal Carcinoma	9	Talaporfin sodium-based PDT	hdmivrputs(whaakddgwr) = cmrumqqqmq edwgdtqosf (slchcpyfxi )	-	01 Feb 2012
ASCO2005	Phase 2	Colorectal Liver Metastases	10	Talaporfin sodium + intratumoral placement of LEDs	gkhrddhtyh(nfeohnbctz) = ssqnevuacs lytqcqhlje (olalsiztou )	-	01 Jun 2005